实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (3): 375-378.doi: 10.3969/j.issn.1672-5069.2022.03.018

• 药物性肝损伤 • 上一篇    下一篇

134例替加环素致药物性肝损伤老年患者临床特征回顾性分析

杨海华, 周聪, 沈国强, 尤晓红, 孟玲   

  1. 214000 江苏省 无锡市第九人民医院药学部(杨海华,尤晓红,周聪);检验科(沈国强);南京医科大学附属第一医院药学部(孟玲)
  • 收稿日期:2021-10-11 出版日期:2022-05-10 发布日期:2022-05-17
  • 通讯作者: 尤晓红,E-mail:wxsyy2003@163.com
  • 作者简介:杨海华,女,42岁,大学本科,主管药师

Clinical feature of tigecycline-induced liver injuries in 134 elderly patients with infection and underlying diseases

Yang Haihua, Zhou Cong, Shen Guoqiang, et al   

  1. Department of Pharmacy, Ninth People's Hospital, Wuxi 214000,Jiangsu Province, China
  • Received:2021-10-11 Online:2022-05-10 Published:2022-05-17

摘要: 目的 总结分析应用替加环素所致药物性肝损伤(DILI)老年患者的临床特征。方法 2018年~2020年我院收治的134例应用替加环素治疗所致的DILI老年患者,对基础疾病、病原学鉴定、肝损伤结果和预后情况进行了分析。结果 在134例患者中,男性占54.5%,女性占45.5%;年龄<70岁患者占41.8%,≥70岁患者占58.2%;所属科室分布主要为重症监护病房、呼吸科和创伤骨科,分别占34.3%、28.4%和16.4%;在基础疾病中,高血压占67.9%,糖尿病占25.4%,恶性肿瘤占23.1%,冠心病占14.2%,慢阻肺占11.2%,骨折占7.5%;联合头孢哌酮/舒巴坦者占94.8%;感染部位主要为肺部感染、骨关节感染和腹腔感染,分别占49.3%、23.1%和13.4%;病原学鉴定结果显示,肺炎克雷伯菌、鲍曼不动杆菌和嗜麦芽窄食单胞菌分别占32.8%、24.6%和17.2%;134例患者在用药1 w后出现肝功能指标异常,在发病2 w时达到高峰,血清TBIL水平为(35.2±5.9)μmmol/L,AST为(69.1±11.5)U/L,ALT为(56.4±9.3)U/L,ALP为(194.8±29.3)U/L,GGT为(134.6±18.9)U/L,在停药和护肝治疗后1 w,TBIL降至(29.1±5.0)μmmol/L,AST降至(57.9±9.6)U/L,ALT降至(50.2±8.6)U/L,ALP降至(183.3±27.4)U/L,GGT降至(126.9±15.4)U/L;肝功能指标恢复正常时间为5~33 d,平均为(14.6±2.3)d;130例患者痊愈,3例自动出院,1例死于多脏器功能衰竭。结论 临床应用替加环素抗感染治疗老年患者容易引发DILI,在用药过程中应密切监测肝功能指标变化,及时处理。

关键词: 药物性肝损伤, 感染, 替加环素, 治疗, 老年人

Abstract: Objective The aim of this study was to retrospectively summarize the clinical feature of drug(tigecycline)-induced liver injuries (DILI) in 134 elderly patients with infection and underlying diseases. Methods The clinical materials of 134 elderly patients with DILI caused tigecycline administration between 2018 and 2020 were summarized retrospectively. The underlying diseases, pathogens and liver function tests were analyzed. Results Among the 134 patients, 54.5% were males and 45.5% were females, with 41.8% of them younger than 70 years old and 58.2% older than 70 years old; the patients hospitalized in Intensive Care Unit, Department of Respiratory Diseases and Department of Orthopaedics accounted for 34.3%, 28.4% and 16.4%; as to the underlying diseases, the hypertension accounted for 67.9%, diabetes for 25.4%, malignant tumors for 23.1%, coronary heart disease for 14.2%, chronic obstructive pulmonary disease for 11.2% and bone fracture for 7.5%; the concomitant administration of cefoperazone/sulbactam accounted for 94.8%; the infected sites included pulmonary, bone and joint, and abdominal cavity infection for 49.3%, 23.1% and 13.4%; the Klebsiella Pneumoniae, Acinetobacter Baumannii and Stenotrophomonas Maltophilia infections accounted for 32.8%, 24.6% and 17.2%; the liver function tests were abnormal one week after intravenous tigecycline administration and peaked at two weeks, with serum bilirubin level of(35.2±5.9)μmmol/L, aspartate aminotransferase level of (69.1±11.5)U/L, alanine aminotransferase level of (56.4±9.3)U/L, alkaline phosphatase level of (194.8±29.3)U/L and acyltranspeptidase level of (134.6±18.9)U/L, which decreased to (29.1±5.0)μmmol/L, (57.9±9.6)U/L, (50.2±8.6)U/L, (183.3±27.4)U/L and (126.9±15.4)U/L one week after discontinuation of tigecycline; the liver function tests returned to normal at day 5 to 33 days, with the average time of (14.6±2.3)days; 130 patients recovered, 3 discharged with abnormal liver function tests and 1 died of multi-organ failures in our series. Conclusion The intravenous administration of tigecycline in treating elderly patients with various infections could cause liver damage, and the surveillance of liver function tests is of particularly importance.

Key words: Drug-induced liver injuries, Infection, Tigecycline, Therapy, Elderly